HKPDNasdaqWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends March 31

Cellyan Biotechnology Co., Ltd

Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Aug 7, 2026

$0.11+0.00 (+1.81%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Debt

Borrowings on the balance sheet, Mar 31, 2026

Cellyan Biotechnology reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Cellyan Biotechnology's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Cellyan Biotechnology's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is HKPD.

Revenue growth-33.9% · median -38.6%

Gross margin10.3% · median 10.3%

Operating margin-17.8% · median -100.8%

Net margin-8.5% · median -159.7%

Company	Revenue	Growth
COSM	$73.73M	+33.8%
HKPD	$13.43M	-33.9%
MEDS	$8.02M	-78.2%
STEK	$2.40M	-38.6%
BHATF	–	–
GVH	–	–

Company

Exchange: Nasdaq
Industry: Wholesale-Drugs, Proprietaries & Druggists' Sundries
Fiscal year ends: March 31
Employees: 2
Auditor: ONESTOP ASSURANCE PAC
SEC CIK: 2007702

Advertisement
300 × 250